WooGene B&G Co., Ltd. announced that it has received KRW 10 billion in funding from Hana Ventures, Aju Investment Co. Ltd., Mirae Asset Daewoo Co., Ltd. and other investor
October 14, 2019
Share
On October 14, 2019, WooGene B&G Co., Ltd. (KOSDAQ:A018620) closed the transaction.
WooGene B&G Co., Ltd. is a Korea-based company mainly engaged in the manufacture of veterinary drugs. The Companyâs products include anti-infective, bulk materials, probiotics, enzymes, antiparasitics, hormone preparations, vaccines, aquacultures, anesthetics, teat dips, disinfectants, pet cure drugs, calcium injections, antiphlogistic injections, enhance metabolism injections, diarrhea remedy injections, sedative injections for swine, toxin binders, pigmentation drugs and others. The Company also provides anti-inflammatory enzymes under the brand name SKD, which are used for human beings. The Company distributes its products within domestic market and to overseas markets, including Iran, Vietnam, Philippines, Brazil and others.
WooGene B&G Co., Ltd. announced that it has received KRW 10 billion in funding from Hana Ventures, Aju Investment Co. Ltd., Mirae Asset Daewoo Co., Ltd. and other investor
WOOGENE B&G CO., LTD 
